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Abstract: Treprostinil is a stable, long-acting prostacyclin analogue which can be admin-
istered as a continuous subcutaneous infusion using a portable miniature delivery system. 
Subcutaneous treprostinil has been shown in a large multicenter randomized controlled trial 
to improve exercise capacity, clinical state, functional class, pulmonary hemodynamics, and 
quality of life in patients with pulmonary arterial hypertension, an uncommon disease of poor 
prognosis. Side effects include facial ﬂ  ush, headache, jaw pain, abdominal cramping, and diar-
rhea, all typical of prostacyclin, and manageable by symptom-directed dose adjustments, and 
infusion site pain which may make further treatment impossible in 7%–10% of the patients. 
Long-term survival in pulmonary arterial hypertension patients treated with subcutaneous 
treprostinil is similar to that reported with intravenous epoprostenol. There are uncontrolled 
data suggesting efﬁ  cacy of subcutaneous treprostinil in chronic thromboembolic pulmonary 
hypertension. Treprostinil can also be administered intravenously, although increased doses, 
up to 2–3 times those given subcutaneously, appear to be needed to obtain the same efﬁ  cacy. 
Preliminary results of a randomized controlled trial of inhaled treprostinil on top of bosentan 
and sildenaﬁ  l therapies have shown signiﬁ  cance on the primary endpoint, which was exer-
cise capacity as assessed by the distance walked in 6 minutes. Trials of oral formulations of 
treprostinil have been initiated.
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Introduction
Treprostinil is used to treat pulmonary arterial hypertension (PAH), which is a 
dyspnea-fatigue syndrome deﬁ  ned by an isolated increase in pulmonary vascular 
resistance (PVR) leading to progressive right heart failure (Farber and Loscalzo 2004). 
In spite of remarkable advances achieved with the introduction of prostacyclins, 
endothelin receptor antagonists (ERA), and phosphodiesterase-5 (PDE-5) inhibitors 
(Humbert et al 2004), the prognosis of PAH remains unfavorable, with estimated medial 
life expectancies of 5–6 years, and insufﬁ  cient clinical improvement in about half of 
the survivors after 1–2 years (McLaughlin et al 2004; Provencher et al 2006).
PAH occurs in association with a variety of conditions, which include connective 
tissue diseases (CTD), congenital heart diseases (CHD), portal hypertension, human 
immunodeﬁ  ciency virus (HIV) infection, and intake of appetite-suppressant drugs, 
mainly fenﬂ  uramines (Simmoneau et al 2004). Recently reported incidences and 
prevalences of PAH range from 2.4 to 7.6 cases per million/year and 15 to 52 per 
million respectively (Humbert et al 2006; Peacock et al 2007).
The diagnosis of PAH is based on a right heart catheterization to demonstrate a 
mean pulmonary artery pressure (Ppa) higher than 25 mmHg at rest and 30 mmHg at 
exercise, a normal left atrial pressure, estimated by a pulmonary artery wedge pressure 
(Ppw) of less than 15 mmHg, a PVR of more than 240 dyne.s.cm–5, and a systematic 
work-up to exclude left heart failure with increased pulmonary venous pressure, respira-
tory diseases and/or hypoxemia, and chronic thromboembolic pulmonary hypertension 
(CTEPH) (Galie et al 2004; Badesch et al 2007).Vascular Health and Risk Management 2008:4(3) 508
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Until in the early 1990s, PAH was a uniformly fatal 
disease, with a median life expectancy of about 2.5 years. 
Uncontrolled studies showed that a small proportion of 
patients responded to high-dose calcium channel blockers, 
retrospective studies supported the use of anticoagulant 
therapy, and “conventional treatment” was otherwise 
limited to life style counseling, diuretics, digitalis, and 
supplemental oxygen (Naeije and Vachiery 2001). Chronic 
continuous intravenous prostacyclin (epoprostenol, Flo-
lan®) was introduced in the 1980s to bridge patients with 
idiopathic PAH (IPAH) to transplantation (Higenbottam 
et al 1993). Epoprostenol was thereafter shown by two 
randomized controlled trials to improve functional state, 
exercise capacity, and survival in idiopathic PAH (Barst 
et al 1996) and to improve functional state and exercise 
capacity in CTD-PAH (Badesch et al 2000). These trials 
led to the FDA approval of epoprostenol for New York 
Heart Association (NYHA) functional classes III and IV 
patients with IPAH in 1996, with label extension to include 
CTD-PAH in 2000.
Extensive experience of long-term treatment with 
chronic intravenous epoprostenol has conﬁ  rmed persistent 
clinical beneﬁ  t over years in IPAH (McLaughlin et al 2002; 
Sitbon et al 2002), CHD-PAH (Rosenzweig et al 1999), 
portal hypertension-associated PAH (Kuo et al 1997), and 
HIV-PAH (Nunes et al 2003). Good long-term results of 
chronic intravenous epoprostenol has led to withdrawal of 
PAH patients from waiting lists for transplantation (Robbins 
et al 1998). Intravenous epoprostenol has been reported to 
help bridging CTEPH patients to thromboendarterectomy 
(Nagaya et al 2003).
Chronic intravenous epoprostenol has been established 
as the gold standard of PAH therapy. It is recommended as 
ﬁ  rst line for NYHA IV patients, and as add-on for patients 
remaining in NYHA functional class III in spite of correctly 
dosed ERA, PDE-5 inhibitors, or both (Galie et al 2004; 
Badesch et al 2007). However, the treatment is not ideal. 
Because of instability and very short half-life (2–7 min), 
epoprostenol must be administered as a continuous infusion 
through a permanently implanted central venous catheter. 
This exposes the patients to a series of complications includ-
ing catheter-related embolism or thrombosis, infections, and 
delivery system malfunctions resulting in poorly tolerated 
rapid overdosing or under-dosing. Therefore, more stable 
prostacyclin derivatives and different routes of administration 
have been developed. The ﬁ  rst to be proposed as an alter-
native to intravenous epoprostenol has been subcutaneous 
treprostinil (Simonneau et al 2002).
Pharmacology of treprostinil
Treprostinil (see Figure 1) is a tricyclic benzindene analogue 
of prostacyclin, and has as such similar anti-platelet and 
vasodilatory actions, including acute pulmonary vasodilation 
(Vachiery and Naeije 2004). This prostanoid is rapidly and 
completely absorbed after subcutaneous administration with 
an absolute bioavailability of 100%. Continuous subcutaneous 
infusion of treprostinil is associated with steady state plasma 
concentrations after about 10 h with administration rates 
from 1.25 to 22 ng/kg/min. The metabolism of treprostinil is 
hepatic, although the enzymes involved are not exactly known. 
Approximately 79% of the administered dose is excreted in 
the urine either as unchanged drug (4%) or an identiﬁ  able 
metabolite (64%). The safety of treprostinil is favorable, with 
in particular no reproductive toxicity or teratogenicity.
The clearance of treprostinil is decreased up to 80% 
in patients with hepatic insufﬁ  ciency, requiring therefore 
cautious dosing in patients with PAH associated with liver 
disease. There are no studies on the pharmacokinetics of 
treprostinil in patients with renal insufﬁ  ciency. Treprostinil 
does not interfere with the metabolism of paracetamol, 
warfarin, or digoxin (Wade et al 2003, 2004). Treprostinil 
is chemically stable in either sterile water or 0.9% sodium 
chloride and 5% dextrose solutions at room temperature, and 
has a close to neutral pH (Phares et al 2003).
Figure 1 Chemical structure of treprostinil sodium (left) and epoprostenol sodium (right).Vascular Health and Risk Management 2008:4(3) 509
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Subcutaneous treprostinil is advantageous compared to 
intravenous epoprostenol because of a less cumbersome 
delivery system and no need for a surgically implanted 
central venous line. Epoprostenol requires sterile daily or 
twice daily reconstitution with ice packing, and is admin-
istered with a variety of more or less bulky portable pump 
systems. In contrast, treprostinil is supplied in 20 mL vials 
containing either 1, 2.5, 5, or 10 mg/mL that may be stored 
at room temperature. In addition, treprostinil is delivered 
via a mini-infusion pump, which is of the size of a small 
cell phone. The injection site is changed approximately 
every 3 days. However, while this is not recommended, 
many patients ﬁ  nd it less painful to leave the subcutaneous 
catheter in place for longer periods of time, up to 2–3 weeks, 
and this seems to be generally well tolerated (Vachiery and 
Naeije 2004).
The pivotal treprostinil trial
The pivotal 12-week trial included 2 parallel North American 
and European international, multicenter, double-blind, 
randomized, parallel, placebo-controlled studies in a total 
of 470 patients aged 8–75 years with PAH (Simmoneau 
et al 2002). This has been until now the largest random-
ized controlled trial ever performed in PAH. The primary 
endpoint was exercise capacity as assessed by the 6-min 
walk distance. Principal reinforcing endopoints were a dys-
pnea-fatigue rating and a clinical score. The clinical score 
included a speciﬁ  ed list of symptoms (dyspnea, orthopnea, 
fatigue, chest pain, dizziness, syncope, palpitations, and 
edema) and signs (loud pulmonic sound, right ventricular 
third sound, right ventricular fourth sound, right ventricular 
heave, tricuspid insufﬁ  ciency murmur, pulmonic regurgita-
tion murmur, hepatomegaly, and jugular vein distension at 
45°). A simpliﬁ  ed clinical score of only 5 of these items, ie, 
dyspnea, fatigue, chest pain, dizziness, syncope, was also 
used and proved equally sensitive to therapy. The second-
ary endpoints were the Borg score and hemodynamics (right 
atrial pressure, Ppa, Ppw, cardiac output heart rate, and mixed 
venous oxygenation saturation). Quality of life (QOL) was 
assessed using the Minnesota Living with Heart Failure 
questionnaire. Six-min walk test, Borg score, dyspnea-fatigue 
rating, clinical score, and QOL were obtained at baseline and 
1, 6, and 12 weeks after randomization. The hemodynamic 
measurements were obtained at baseline and 12 weeks after 
randomization. The two studies were analyzed individually 
as well as together.
Treprostinil was initiated at a ﬁ  xed dose of 1.25 ng/kg/min 
(or half this dose if not tolerated), and then progressively 
increased if tolerated by 1.25 ng/kg/min during the ﬁ  rst 4 
weeks, then by 2.5 ng/kg/min per week until a maximum of 
22.5 ng/kg/min at week 12. In fact, the ﬁ  nal doses achieved 
remained below these target doses, at 9.3 ± 0.4 ng/kg/min in 
the treprostinil group, and 19.1 ± 0.3 ng/kg/min in the placebo 
group. This was explained by slowing of dose escalation 
because of infusion site pain.
The two study groups were comparable in age, gender 
distribution, and severity of pulmonary hypertension, with 
82% of the patients in NYHA functional class III, 11% in 
NYHA class II, and 7% in NYHA class IV, and an average 
baseline 6-min walk distance of 326 m. Subsets of PAH 
were IPAH in 58% of the patients, CTD-PAH in 19%, and 
CHD-PAH in 23%.
In analyzing both studies together, the overall median 
6-min walk increased by 10 m in the treprostinil group, and 
did not change in the placebo group, with a between-group 
effect of 16 m (p = 0.0064). It is interesting that the two 
studies did not reach a p  0.05 level of signiﬁ  cance on 
the placebo-substracted change in the 6-min walk distance 
(p = 0.0607 and 0.055, respectively). The pre-speciﬁ  ed cri-
teria, ie, pooled p  0.01 with one of the two trials with a 
p  0.05, were not achieved, but it appeared reasonable to 
conclude that the results showed a treatment effect of trepro-
stinil in PAH, because of signiﬁ  cant directional changes 
in all the reinforcing and secondary endpoints. As in other 
prostacyclin trials in IPAH or CTD-PAH, hemodynamic 
changes after 12 weeks of treatment, though signiﬁ  cant, 
were relatively minor: in the treprostinil and placebo groups, 
respectively, Ppa +2.3 vs –0.7 mmHg and cardiac output 
+0.12 vs –0.06 L/min/m2. On the other hand, both the 6-min 
walk distance and the clinical score was already signiﬁ  cantly 
improved by treprostinil after 6 weeks of treatment, illustrat-
ing the relevance of the 6-min walk distance to detect clinical 
changes in PAH patients.
A covariate analysis showed no interactions between 
treprostinil treatment effect and age, gender, race, or diag-
nostic category. However, an a posteriori subgroup analysis 
showed similar responses to treprostinil in IPAH and CTD-
PAH, but no signiﬁ  cant change in 6-min walk distance in 
CHD-PAH. This difference was explained by the inhomo-
geneous character of that subgroup, and also by the fact that 
CHD-PAH tends to be stable for much longer periods of time 
than other PAH categories. On the other hand, there were 
signiﬁ  cant interactions between treprostinil treatment effect 
and NYHA functional class, baseline 6-min walk distance, 
and SvO2. The 6-min walk distance was improved by 54 m 
in the 34 patients in NYHA class IV, 17 m in the 382 patients Vascular Health and Risk Management 2008:4(3) 510
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in NYHA class III, and only 2 m in the 53 patients who were 
in NYHA class II.
In fact, there was a dose relationship such that the higher 
the treprostinil dose achieved, the greater the increase in 
6-min walk distance. Based on this observation, the aver-
age dose achieved in the treprostinil group was only 9.3 
ng/kg/min, far below the target 22.5 ng/kg/min dosing, 
thereby preventing full disclosure of treprostinil efﬁ  cacy. It 
was indeed only later the experience of many centers that 
infusion site pain is not directly dependent on the rate of 
treprostinil dose increase.
Infusion site pain occurred in 85% of the treprostinil-
treated patients and in 27% in the placebo-treated patients. 
Eighteen patients (8%) in the treprostinil group discontinued 
their study treatment due to intolerable abdominal infusion 
site pain versus one in the placebo group. Other adverse 
events were those classically related to the use of prostacyclin 
such as diarrhea, jaw pain, ﬂ  ushing, and lower limb edema, 
which mainly occurred more often in the treprostinil group. 
There were no other signiﬁ  cant side effects.
Long-term observations
The effects of long-term subcutaneous treprostinil have 
been reported in 860 patients with PAH (Barst et al 2006). 
In that study, the initial clinical improvement was sustained 
in the majority of patients, and survival was globally 87% 
at 1 year and 68% at 4 years, with 91%–72% for a subset 
of IPAH patients. In 23% of the patients, the treatment was 
discontinued because of adverse events, and in 11% switched 
to an alternative prostacyclin analogue. Bosentan was added 
in 105 patients (12%) and sildenaﬁ  l in 25 (3%).
In another long-term observational study on a total of 99 
PAH patients and 23 inoperable CTEPH patients, the NYHA 
functional class declined from 3.2 to 2.1 with persistent 
improvement in the 6-min walk distance, on average by 100 m 
(Figure 2). The 1- and 3-year survival rates were 89% and 
71%, with, interestingly, event-free survival rates of 83% and 
69%. The mean dose of treprostinil at 3 years was on average 
around 40 ng/kg/min (Figure 3). There were only 5% of 
treatment interruptions because of local infusion site pain.
These long-term observations suggest that subcutaneous 
treprostinil is a valid alternative to intravenous epoprostenol 
as a gold standard of PAH therapy (Galie et al 2004; Badesch 
et al 2007).
Transitioning
Transition from intravenous epoprostenol to subcutaneous 
treprostinil has been achieved in a number of patients. Ini-
tially undertaken because of life-threatening complications 
of chronic intravenous epoprostenol therapy, such as embolic 
stroke and repeated sepsis (Vachiery et al 2002), the proce-
dure is now also performed in several centers on the request of 
patients for the purpose of increased autonomy and comfort. 
Transitioning should be performed in a hospital environment 
Figure 2 Long-term effects of subcutaneous treprostinil on exercise capacity in patients with severe pulmonary hypertension, with indication of treprostinil dose and 6MWD 
(6-min walk distance). Drawn from data of Lang et al (2006).Vascular Health and Risk Management 2008:4(3) 511
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under the supervision of a medical team experienced in the 
treatment of PAH. Under noninvasive hemodynamic moni-
toring including heart rate and blood pressure measurements 
and echocardiography as needed, epoprostenol is progres-
sively decreased and treprostinil increased, with overdosing 
and underdosing symptoms-directed adjustments, in no more 
than 1–4 days. Usually the same clinical state and exercise 
capacity is obtained under a treprostinil dose that is about 
80% of the previous epoprostenol dose. Most transitioned 
patients express satisfaction and relief, in spite of local 
infusion site pain, and present with continued improvement 
in exercise capacity over time.
There has been recently a report on 22 PAH patients 
treated with intravenous epoprostenol who were randomized 
for 8 weeks to subcutaneous treprostinil versus a placebo 
(Rubenﬁ  re et al 2007). This represents the only withdrawal 
trial reported in PAH. Even though the protocol speciﬁ  ed that 
patients with clinical deterioration would be rapidly returned 
to intravenous epoprostenol, most experts would be reluctant 
to repeat such a study. Patients who deteriorate after inter-
ruption of any prostacyclin therapy may be difﬁ  cult to bring 
back to their previous clinical state. However, no irreversible 
deterioration occurred in this tightly monitored trial. Seven 
of the 8 patients withdrawn to placebo had the expected 
clinical deterioration, while this was observed in only 1 
of the 14 patients withdrawn to subcutaneous treprostinil. 
The authors concluded that subcutaneous treprostinil is 
effective in PAH and maintains functional status in patients 
transitioned from intravenous epoprostenol (Rubenﬁ  re et al 
2007).
Treprostinil can be formulated for intravenous adminis-
tration. Intravenous treprostinil has been reported to improve 
exercise capacity, Borg dyspnea score, NYHA functional 
class, and hemodynamics after 12 weeks of therapy compared 
with baseline (Tapson et al 2006). Accordingly, patients 
treated with intravenous epoprostenol have been safely 
switched to intravenous treprostinil (Gomberg-Maitland et al 
2005; Sitbon et al 2007). However, while the dosing of sub-
cutaneous treprostinil is about the same as that of intravenous 
epoprostenol (Vachiery et al 2002), the dose of intravenous 
treprostinil has been reported to be at least doubled to main-
tain the clinical beneﬁ  t (Gomberg-Maitland et al 2005; Sitbon 
et al 2007). Patients have also been switched from subcutane-
ous to intravenous treprostinil in several PAH centers, with 
the same apparent need to rapidly double the dose to attain 
similar efﬁ  cacy. There is no explanation for this discrepancy, 
as bioequivalence of intravenous and subcutaneous trepro-
stinil has been reported in normal volunteers at steady state, 
after 72 hours of continuous administration (Labilerte et al 
2004). Most recently, this bioequivalence, with the same 
dose versus plasma levels relationship, was conﬁ  rmed for 
PAH patients over a wide range of therapeutic doses, up to 
125 ng kg/min (McSwain et al 2008). The problem of optimal 
dosing with intravenous versus subcutaneous treprostinil in 
Figure 3 Effects of subcutaneous treprostinil on survival in patients with idiopathic pulmonary arterial hypertension (PAH). Survival curves of similar patients treated with 
intravenous epoprostenol and those of historical controls are also shown. Drawn from data of McLaughlin et al (2002) and Lang et al (2006).Vascular Health and Risk Management 2008:4(3) 512
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PAH patients may have to be revisited with the complete 
range of clinical and hemodynamic endpoints usually applied 
in PAH trials (Simmoneau et al 2002).
Any continuous drug administration through an 
implanted central venous catheter carries a risk of line infec-
tion and sepsis. While the overall incidence of this severe 
complication is very low, there has been a recent concern 
about an increased number of gram-negative bloodstream 
infections in patients treated with intravenous treprostinil 
compared with intravenous epoprostenol (CDC 2007). This 
problem appears to be related to differences in prepara-
tion and storage, and should be overcome by tightening of 
sterility precautions.
An inhaled formulation of treprostinil is currently being 
evaluated with encouraging preliminary results (Channick 
et al 2006). The preliminary results of a randomized con-
trolled trial of inhaled treprostinil on top of bosentan or 
sildenaﬁ  l therapies have been reported as a press release, 
with a signiﬁ  cance on the primary endpoint, the 6-min 
walk distance. A more detailed report on these results 
will be hopefully presented soon at a scientiﬁ  c meeting. 
Randomized controlled trials of an oral formulation of 
treprostinil are ongoing.
Treprostinil for CTEPH
As already mentioned, subcutaneous treprostinil has been 
occasionally used to treat patients with inoperable CTEPH 
(Lang et al 2006). The rationale is that pulmonary hyper-
tension in these patients may be essentially accounted for 
by distal vasculopathy, which is actually hispathologically 
similar to PAH (Hoeper et al 2006). The effects of subcutane-
ous treprostinil have been recently reported in 25 inoperable 
CTEPH patients included in an open-label uncontrolled 
study (Skoro-Sajer et al 2007). All patients were in NYHA 
functional classes III or IV, had a 6-min walk distance of 
less than 380 m, and had undergone at least 1 previous 
hospitalization for right heart failure within the previous 6 
months. The patients were compared to matched historical 
inoperable CTEPH controls. The patients were followed for 
19 ± 6 months. Treprostinil treatment improved survival, 
increased the 6-min walk distance, improved NYHA func-
tional class, decreased B-type natriuretic peptide, increased 
cardiac output and decreased PVR. Treprostinil plasma levels 
correlated with drug dose over time, indicating persistently 
stable absorption, in spite of local reactions in 86% of cases. 
Thus, subcutaneous treprostinil shows as an interesting 
therapeutic option for patients with inoperable CTEPH. 
Subcutaneous treprostinil offers perspective for the treatment 
of persistent postoperative pulmonary hypertension, or for 
the preoperative conditioning of patients for surgery in case 
of excessively high PVR, known to be a poor operative risk. 
However, these possible indications will have to be conﬁ  rmed 
in properly designed randomized controlled trials.
Indications and usage
Chronic subcutaneous treprostinil has a place in the treatment 
algorithm of patients with PAH in functional classes II, III, 
and IV (Galie et al 2004; Badesch et al 2007).
The recommendation is to start treprostinil at the dose 
of 1.25 ng/kg/min, which is increased by 1.25 ng/kg/min 
per week during the ﬁ  rst 4 weeks, then by 2.5 ng/kg/min 
per week until the maximum clinical improvement with no 
excessive prostacyclin-type side effects. However, in practice 
most centers now start at 2.5 ng/kg/min and increase in a few 
days to reach 10 ng/kg/min after a week and 15–20 ng/kg/min 
after 2 weeks according to tolerance. Weekly adaptations are 
applied afterwards, aiming at optimal clinical efﬁ  cacy with 
minimal side effects. This strategy appears to be safe, allows 
for more rapid and effective relief in severely ill patients, and 
outruns the local infusion site pain, which is of course better 
tolerated in the context of decreased dyspnea and fatigue.
Local infusion site pain will occur in around 80% of 
patients, and may be intolerable in 6%–15% of them. It var-
ies markedly from one patient to another, from one infusion 
site to another, is primarily related to initiation of infusion, 
and often, but not always, improves after several months. 
It is usually worse during the ﬁ  rst days following a change 
of infusion site, and may sometimes impair the ability of a 
patient to perform a 6-min walk test. It has been our experi-
ence that the administration of more concentrated solutions, 
starting with 2.5 mg/mL to progress as soon as possible to 
the use of 5 mg/mL or 10 mg/mL vials, decreases the local 
pain by decreasing the amount of volume infused for the 
same dose. The pain is otherwise generally manageable by 
relocation of infusion site, cold or hot compresses, a variety 
of local ointments, and paracetamol. Sometimes, a short 
course of high dose corticosteroids, such as prednisolone 
2 mg/kg/day during several days, may help the patient 
through, and narcotic drugs have been used in some centers. 
These more aggressive interventions may appear necessary 
when patients present with severe pain that reduces quality 
of life. In these cases, especially if on high dose treprostinil, 
transitioning to intravenous epoprostenol may fail because 
of major prostacyclin-type side effects of equivalent dose 
intravenous epoprostenol, and carries the risk of clinical 
destabilization. It is therefore preferable to switch from Vascular Health and Risk Management 2008:4(3) 513
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subcutaneous to intravenous treprostinil, bearing in mind 
that higher doses may be needed, and particular attention 
should be paid to sterility of manipulations.
It has been the experience in expert centers in general 
that prostacyclin-type side effects tend to be less severe with 
treprostinil than with epoprostenol, allowing for more rapid 
increase in dosing and symptomatic relief. The reasons for 
this better tolerance of treprostinil are unclear, but may be 
related to less rapid increases in plasma levels.
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